|
Impella cp smartassist was inserted via left femoral artery access in a 33-year-old male patient presenting with idiopathic cardiomyopathy.The patient's comorbidities and society for cardiovascular angiography and interventions (scai) shock stage prior to initiation of support were not documented.The clinical course was identified through published literature; therefore, limited information regarding the duration of support and procedural details was available.The publication reported that the patient received heparin anticoagulation with an activated clotting time (act) of 160 seconds prior to the procedure and maintained act values between 160 and 200 seconds during support.Following completion of treatment and impella cp smartassist explant, bleeding was observed at the femoral access site.Evaluation identified a femoral artery dissection with an associated vessel wall defect.The treating physician performed surgical intervention, including arterial clamping and repair of the vessel defect using a 6-0 nesplen patch.Following completion of the repair, clamps were released and hemostasis was achieved.Reported operative time was 15 minutes with an estimated blood loss of 150 cc.The postoperative course was uneventful.The patient was extubated the following day, and contrast-enhanced computed tomography performed on postoperative day 7 demonstrated no abnormalities at the repair site.Sutures were removed on postoperative day 8, and the patient continued medical management without reported sequelae.No additional clinical, hemodynamic, or device performance information was provided within the publication.The femoral artery dissection and bleeding were observed following device explant and required surgical repair.Based on the available information, the contribution of access technique, anticoagulation management, underlying vascular anatomy, or other patient-specific factors cannot be determined.
|
|
Product complaint # (b)(4).This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by abiomed inc or its employees that the report constitutes an admission that the product, abiomed inc, or its employees, caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|